GlassScriptPhysician profile
Rajayogesh Davuluri
NPI 1972865731
$3,984.21
in general payments reported to CMS, 2019-2025
44 companies · $722 in 2025
The $722 reported for 2025 was more than what 80% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.35 · 2020: $98.00 · 2022: $498 · 2023: $758 · 2024: $1,842 · 2025: $722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,247 · Consulting Fee: $1,075.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,247.34 |
| Consulting Fee | $1,075.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,242.27 | 2022-2025 | Imfinzi, Tagrisso, Enhertu |
| Merck Sharp & Dohme LLC | $385.67 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $260.15 | 2022-2025 | Rybrevant, Darzalex, Tecvayli |
| Daiichi Sankyo INC. | $205.89 | 2022-2025 | Enhertu, Datroway |
| Sobi, INC | $180.44 | 2022-2025 | |
| Pfizer INC. | $138.40 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $107.69 | 2019-2025 | |
| Seagen INC. | $105.62 | 2022-2023 | Tukysa, Adcetris, Padcev |
| Emd Serono, INC. | $98.85 | 2023-2025 | Bavencio |
| Astellas Pharma US INC | $98.00 | 2020 | |
| Gilead Sciences, INC. | $88.58 | 2023-2025 | Trodelvy |
| Genzyme Corporation | $88.27 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $76.50 | 2024 | |
| Incyte Corporation | $71.09 | 2023-2025 | Jakafi, Monjuvi, Niktimvo |
| Abbvie INC. | $69.61 | 2023-2025 | Venclexta |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajayogesh Davuluri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.